Autoimmune disease treating drug

An immunosuppressive agent, an autoimmune disease curative, an immunosuppression potentiator, and a cell adhesion inhibitor each containing a thienotriazolodiazepine compound with a 2-alkylated diazepine ring as an active ingredient; immunosuppression, cure of autoimmune diseases, potentiation of immunosuppression, and inhibition of cell adhesion each comprising the administration of the above compound; and the use of this compound for producing the above drugs. 4-(2-chlorophenyl)-6, 9-dimethyl-6H-thieno [3,2-f] [1,2,4] triazolo-[4,3-a] [1,4] diazepine, morpholide of 3- [4-(2-chlorophenyl)-6, 9-dimethyl-6H-thieno [3,2-f] [1,2,4] triazolo [4,3-a] [1,4]-diazepin-2-yl) propionic acid, optical isomers of them, and (+)-6-(2-chlorophenyl)-3-cyclopropanecarbonyl-1,1-dimethyl-2,3,4,5-tet rahydro-8H-pyrido[4',3':4,5]-thieno[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepine enhance the activity of an immunosuppressive agent, such as cyclosporin, and per se have the activities of autoimmune suppression and cell adhesion inhibition, thus being useful as the above-mentioned drugs.